SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-016468
Filing Date
2023-10-16
Accepted
2023-10-16 17:29:22
Documents
17
Period of Report
2023-10-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apre-20231016x8k.htm   iXBRL 8-K 39506
2 EX-99.1 apre-20231016xex99d1.htm EX-99.1 10884
3 GRAPHIC apre-20231016xex99d1g001.jpg GRAPHIC 251906
4 GRAPHIC apre-20231016xex99d1g002.jpg GRAPHIC 154399
5 GRAPHIC apre-20231016xex99d1g003.jpg GRAPHIC 158440
  Complete submission text file 0001558370-23-016468.txt   962815

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20231016.xsd EX-101.SCH 3998
7 EX-101.DEF apre-20231016_def.xml EX-101.DEF 2847
8 EX-101.LAB apre-20231016_lab.xml EX-101.LAB 17248
9 EX-101.PRE apre-20231016_pre.xml EX-101.PRE 11358
11 EXTRACTED XBRL INSTANCE DOCUMENT apre-20231016x8k_htm.xml XML 4907
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 231328064
SIC: 2834 Pharmaceutical Preparations